BioMarin Pharmaceutical Inc.
105 Digital Drive
About BioMarin Pharmaceutical Inc.
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored.
BioMarin offers a friendly, fast-paced, collegial environment where success is measured by both the individual and collective efforts of hundreds of talented scientists, business professionals, technical specialists and experts in a variety of fields from sales and marketing, to finance, to manufacturing, to clinical and regulatory operations.
BioMarin is growing rapidly to support the development and global commercialization of breakthrough drugs to treat rare genetic diseases. The company’s product portfolio comprises seven approved products and multiple clinical and pre-clinical product candidates.
You can make it happen at BioMarin, where the unique combination of big-company success in a small-company environment provides unparalleled opportunity for individual contributions and growth.
What makes working here unique? At BioMarin, we feel the intense tie between the work we do and the life-changing results it delivers. Our focus on rare disease gives us the rare opportunity to truly impact lives.
582 articles with BioMarin Pharmaceutical Inc.
BioMarin Announces Ongoing Study Demonstrates Durable Treatment Benefit from Brineura® (cerliponase alfa) for 3 Years
Reduced Rate of Decline Maintained in Children with CLN2 Disease, a Form of Batten Disease
Presentations to Highlight Results from Studies for the Treatment of Three Forms of MPS and CLN2 Disease, a Form of Batten Disease
BioMarin to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast on Thursday, February 21 at 4:30pm ET
BioMarin Pharmaceutical Inc. announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 21, at 4:30 p.m. ET to discuss fourth quarter and full year 2018 financial results and provide a general business update.
BioMarin Highlights Key Milestones for 2019 at 37th Annual J.P. Morgan Healthcare Conference in San Francisco
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a company focused on innovative therapies to treat rare diseases, provided highlights to the investment community on its key milestones for 2019 at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 8:30 am PT, or 11:30 am ET, in San Francisco, California.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in Citi's 13th Annual Biotech Conference on December 5 in New York City.
BioMarin Pharmaceutical Inc. today announced the promotion of Amy Wireman to Group Vice President, Human Resources.
Florida-based Catalyst Pharma won regulatory approval for its treatment of a rare autoimmune disorder called Lambert-Eaton myasthenic syndrome (LEMS). The U.S. Food and Drug Administration approval of the new oral drug, Firdapse (amifampridine), is the first ever approved for this disease.
'Hemophilia: The Musical' allows teens to share their experiences with the genetic disease.
SAN RAFAEL, Calif., /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the debut of the Broadway-style 'Hemophilia: The Musical,' a first-of-its-kind theatrical production featuring 25 students affected by a bleeding disorder.
Credit Suisse 27th Annual Credit Suisse Healthcare Conference on November 13 in Scottsdale, AZ
BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on November 7th in New York
Vosoritide for Achondroplasia: Demonstrates Continued Increased Growth through 42 months in Phase 2; Global Phase 3 Fully Enrolled
BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on November 7th in New York
Key Research & Development Pipeline Products and Data to be Presented
10/29/2018Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more.
First Nine Months of 2018 Total Revenues Grow 19% Year-over-year to $1.14 Billion
10/22/2018The U.S. Bureau of Labor Statistics predicts a 7 percent increase in jobs for biomedical engineers and a 13 percent increase in medical scientists.
Multiple biotech companies are scheduled to release their quarterly reports next week. BioSpace takes a quick look at some these companies and the announcements they have made through 3Q2018.
The U.S. FDA approved Pfizer’s PARP inhibitor, Talzenna (talazoparib), for patients with a germline BRCA-mutated (gBRCAm), HER2-negative breast cancer. The agency also approved Myriad Genetics’ diagnostic assay to identify the mutation.
BioMarin Receives Milestone Payments from Pfizer for Talzenna® (Talazoparib) for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Company earned $15 million in milestone payments from Pfizer Inc.